IP Library Granted Patent US 10,745,493
Granted Patent B2
US 10,745,493 · App. 15/540,461 · Granted Aug 18, 2020

Graft copolymer

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,745,493
App. No.
15/540,461
Granted
Aug 18, 2020
Kind
B2
Abstract

A graft copolymer comprising: a core polymer comprising a crosslinked or non-crosslinked polysaccharide, a plurality of primary graft polymers covalently grafted to the core polymer, a plurality of secondary graft polymers covalently grafted to each primary graft polymer, an injectable dermal aesthetic formulation comprising such a graft copolymer and a method of preparing such a graft copolymer.

Claims (20)

1. A graft copolymer comprising:

(a) a core polymer comprising a crosslinked hyaluronic acid, and

b) a plurality of dextran polymers covalently grafted to the core polymer; wherein the plurality of dextran polymers consist of a plurality of chondroitin sulphate polymers grafted to each dextran polymer.

2. The graft copolymer according to claim 1 , wherein the core polymer has a molecular weight in the range of 50-5000 kDa.

3. The graft copolymer according to claim 1 , wherein the core polymer comprises a polysaccharide gel.

4. The graft copolymer according to claim 1 , wherein the dextran polymers comprise a water soluble polymer.

5. The graft copolymer according to claim 1 , wherein the dextran polymers have a molecular weight in the range of 1-1000 kDa.

6. The graft copolymer according to claim 1 , wherein the chondroitin sulphate polymers have a molecular weight in the range of 10-1000 kDa.

7. The graft copolymer according to claim 1 , wherein the dextran polymers are covalently grafted, directly or through a linking group, to the core polymer by single end-point attachment.

8. The graft copolymer according to claim 1 , wherein the chondroitin sulphate polymers are covalently grafted, directly or through a linking group, to the primary graft dextran polymers by single end-point attachment.

9. An injectable dermal aesthetic formulation comprising the graft copolymer according to claim 1 .

10. The graft copolymer according to claim 2 , wherein the core polymer has a molecular weight in the range of 100-1000 kDa.

11. The graft copolymer according to claim 6 , wherein the chondroitin sulphate polymers have a molecular weight in the range of 20-500 kDa.

12. A method of preparing a graft copolymer, comprising:

a) providing a core polymer comprising a crosslinked or non-crosslinked polysaccharide comprising a plurality of pendant functional groups,

b) providing a primary graft polymer comprising a terminal functional group and a plurality of pendant functional groups,

c) providing a secondary graft polymer comprising a terminal functional group,

d) mixing the core polymer with the primary graft polymer under conditions allowing covalent binding of the primary graft polymer exclusively to the pendant functional groups of the core polymer via the terminal functional group of the primary graft polymer,

e) mixing the grafted product of step d) with the secondary graft polymer under conditions allowing covalent binding of the secondary graft polymer exclusively to the pendant functional groups of the primary graft polymer via the terminal functional group of the secondary graft polymer,

wherein the core polymer is a crosslinked hyaluronic acid, the primary graft polymer is dextran and the secondary graft polymer is chondroitin sulphate.

Assignments (5)
CHANGE OF ADDRESS Recorded Jun 28, 2022
From: GALDERMA HOLDING SA
To: GALDERMA HOLDING SA
Reel/Frame 060541/0374 →
CORRECTIVE ASSIGNMENT TO CORRECT THE THE ASSIGNEES ADDRESS PREVIOUSLY RECORDED AT REEL: 057652 FRAME: 0859. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Dec 13, 2021
From: GALDERMA S.A.
To: NESTLÉ SKIN HEALTH S.A.
Reel/Frame 058495/0582 →
CHANGE OF NAME Recorded Sep 29, 2021
From: NESTLÉ SKIN HEALTH S.A.
To: GALDERMA HOLDING SA
Reel/Frame 057631/0589 →
AMENDMENT TO ASSET TRANSFER AGREEMENT Recorded Sep 29, 2021
From: GALDERMA S.A.
To: NESTLÉ SKIN HEALTH S.A.
Reel/Frame 057652/0859 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 8, 2018
From: BERGMAN, KRISTOFFER
To: GALDERMA S.A
Reel/Frame 044872/0317 →